echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical World News > Study on the economic operation of biomedical industry in Shanghai

    Study on the economic operation of biomedical industry in Shanghai

    • Last Update: 2020-02-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    By Liao Yitao At present, the trend of global, national and regional biomedical industry pattern's fission and reorganization is prominent, and presents three major trends of clustering, long tail and integration As the core city of innovation resources gathering in the Yangtze River Delta, Shanghai, with the construction of science and technology innovation center with global influence, has continuously consolidated its development foundation, and the potential of biomedical industry is further strengthened, showing that With complete system, solid foundation and concentrated development, it has gradually formed a high-end R & D, manufacturing and service outsourcing center for the pharmaceutical industry in the Asia Pacific region In recent years, the growth rate and profit margin of Shanghai's biomedical industry rank in the forefront of the city's strategic emerging industries According to the data of Shanghai biomedical technology industry promotion center, in 2018, the total economic volume of Shanghai biomedical industry reached 343.388 billion yuan, further consolidating the important pillar position of biomedical industry in the city, and forming the basic pattern of "equal emphasis on three industries" of pharmaceutical manufacturing industry, business and R & D service outsourcing Among them, the total industrial output value of Shanghai biomedical manufacturing industry was 117.66 billion yuan, an increase of 9.8%, and the main business income was 119.827 billion yuan Figure 1 total economic volume and growth rate of Shanghai biomedical industry in 2013-2018 (100 million yuan) From the contribution of the industrial output value of biomedical manufacturing industry in each district and county, in 2018, Shanghai biomedical industry was dominated by Pudong New Area, Minhang, Fengxian, Jiading, Jinshan, Qingpu and other regions, accounting for 92.6% of the city's output value Among them, the output value of Pudong New Area is 54.816 billion yuan, an increase of 16.2%; Minhang District is 20.599 billion yuan, an increase of 1%; Fengxian District is 16.149 billion yuan, an increase of 4.9%; Jiading District is 6.538 billion yuan, an increase of 3%; Jinshan District is 6.471 billion yuan, an increase of 20.2%; Qingpu District is 4.394 billion yuan, an increase of 7.5% Figure 2 total output value and growth rate of biomedical manufacturing industry in Shanghai in 2018 (100 million yuan) From the perspective of the main income of the biomedical manufacturing industry, the proportion of APIs and preparations manufacturing is the largest, followed by medical devices and biological, biochemical products manufacturing, traditional Chinese medicine manufacturing, and pesticide manufacturing is relatively small Among them, in 2018, the main business income of Shanghai chemical pharmaceutical manufacturing industry reached 42.5 billion yuan, an increase of 18.7%; the main business income of chemical original pharmaceutical manufacturing industry reached 12.065 billion yuan, an increase of 21.5%; the main business income of biological and biochemical products manufacturing industry reached 14.192 billion yuan, an increase of 11.5%; the main business income of medical equipment and device manufacturing industry reached 26.216 billion yuan, an increase of 10.6% The main business income of TCM manufacturing industry reached 10.222 billion yuan, an increase of 0.2% Figure 3 main revenue and growth rate of biomedical manufacturing industry in Shanghai (100 million yuan) At present, Shanghai focuses on biopharmaceuticals, chemicals, high-end medical devices, R & D outsourcing and other fields According to the action plan for promoting the high quality development of Shanghai biomedical industry (2018-2020), Shanghai biomedical industry will focus on promoting the industrialization development of major pharmaceutical innovation achievements in the future In the field of biological products, we will focus on promoting the R & D and industrialization of products such as antibody drugs, new vaccines, proteins and polypeptides In the field of innovative chemical drugs, we will focus on promoting drug research and development in the fields of tumor, cardiovascular and cerebrovascular diseases, diabetes, neurodegenerative diseases, respiratory diseases, major infectious diseases, and accelerate the industrialization of achievements In the field of medical devices, it focuses on innovative and high value-added products such as digital medical imaging equipment, high-end treatment equipment, minimally invasive intervention and implantation medical devices, clinical diagnostic instruments, etc., so as to accelerate the industrialization 1 Enterprise scale According to the flint creation database, in the past five years, the number of biomedical enterprises in Shanghai has shown an annual growth trend of about 20% By the end of 2019, the total number of pharmaceutical and health enterprises in Shanghai has reached 94738, including 8616 key biomedical enterprises (including medical device enterprises with medical device products (class II and class III); pharmaceutical production achievements (including drug acceptance) , clinical application, clinical stages); production and operation enterprises with GMP and GSP certification; R & D enterprises with biomedical related patents and papers.) There are 4451 biomedical production and R & D enterprises, 9 Unicorn enterprises and 69 listed enterprises The total market value of listed enterprises is 632.95 billion yuan, and the main business income of listed enterprises is 125.792 billion yuan (mid-2019) Figure 4 growth trend of the number of medical and health enterprises in Shanghai in 2015-2019 2 Enterprise field According to the flint creation database, by the end of December 2019, key enterprises in Shanghai's biomedical industry were mainly composed of pharmaceutical businesses, medical devices, industrial services and pharmaceutical enterprises Among the 8616 key biomedical enterprises in the city, 5231 are pharmaceutical commercial enterprises, 2056 are medical equipment enterprises, 853 are pharmaceutical enterprises, 1531 are industrial service enterprises, and 373 are medical service enterprises Figure 5 distribution of key areas of biomedical enterprises in Shanghai in 2019 From the perspective of the agglomeration and distribution of enterprises in various districts and counties, Shanghai biomedical enterprises have shown a multi-point flowering situation, with a large number and relatively scattered distribution, mainly concentrated in Pudong, Fengxian, Jinshan, Qingpu, Jiading, Baoshan, Minhang, Songjiang, Xuhui and Putuo districts, but the industrial overlap among the districts has not yet formed a clear pattern of industrial coordination Figure 6 distribution heat map of Shanghai biomedical Enterprises In the ten major concentration areas of medical and health industry in Shanghai, in terms of the number of enterprise clusters, Fengxian District, Pudong New Area, Jinshan District and other three places have gathered more than 10000 medical and health enterprises, becoming the core area of the development of medical and health industry in Shanghai In terms of the proportion of high-tech enterprises, Xuhui District has the highest proportion, followed by Pudong New Area and Minhang District, which are 1.57%, 1.13% and 1.0% respectively Figure 7 proportion of the total number of enterprises and high-tech enterprises in the main concentration areas and counties of Shanghai Medical and health industry in 2019 From the perspective of Industrial Park agglomeration, at present, Shanghai biomedical industry relies on Shanghai Zhangjiang High tech Industrial Development Zone, Shanghai International Medical Park, Fenglin Life Science Park, Shanghai Industrial Comprehensive Development Zone, Shanghai Songjiang Economic Development Zone, Shanghai New Hongqiao International Medical Center, Caohejing emerging technology development zone, Shanghai Zizhu high tech Industrial Development Zone, Shanghai Shangzhi Haijinshan Industrial Park, Shanghai Qingpu Industrial Park, Shanghai Xinghuo Industrial Park, Jinshan Second Industrial Park, Jiading precision medical and health service cluster, putuotaopu International Health Innovation Industrial Park, Luodian Industrial Park and other industrial park carriers form a unique biomedical industry cluster According to the data of flint creation database, by the end of December 2019, Shanghai had 18261 domestic invention patents, 1472 drug clinical trials, 2055 new drugs of class I and II accepted by CDE, 3974 domestic drugs, 18 new drugs of class I and class III approved by CDE, and 7 varieties, 2 and 3 types of medical treatment that passed the consistency evaluation of generic drugs 4602 devices (first registration) 1 Innovation platform According to the flint creation database, by the end of December 2019, Shanghai's biomedical industry had 16 state-level key laboratories, 17 state-level biomedical industry incubators, 17 universities, and initially built an industrial service platform system covering all aspects of the industry chain, including early drug research, pre clinical research, clinical research, approval and launch Figure 8 Shanghai Industrial Innovation Service Platform System 2 Human resources According to the data of Huoshi creation database, as of December 2019, Shanghai has 981 national level talents and 410 municipal level talents in the field of biomedical industry, including 85 Yangtze River scholars, 248 national thousand talents program, 34 National 863 scientists, 144 Chinese Academy of Sciences hundred talents program, 49 academicians of Chinese Academy of Sciences and 35 academicians of Chinese Academy of engineering 3 Clinical resources According to the data of Huoshi creation database, by the end of December 2019, Shanghai had 34 top three hospitals, including Tongji Hospital, Oriental Hospital, Huashan Hospital Affiliated to Fudan University, the first people's Hospital, the Sixth People's Hospital and the Tenth People's hospital According to the data of Huoshi creation database, by the end of December 2019, 1139 financing events had occurred in Shanghai biomedical industry, with 645 financing enterprises and a total financing amount of 9.14 billion yuan Among them, financing activities in Angel round, a round, B round and strategic financing were relatively active, with 233, 373, 153 and 115 respectively In terms of the actual investment activities, the main financial investment institutions active in Shanghai are Sequoia China, gaotejia investment, Qiming venture capital, Junlian capital, Tonghe capital, Gaoling capital, Kangqiao capital, Temasek, China venture capital, Yunfeng fund, Softbank China capital, Jingwei China, IDG capital, etc At the same time, Shanghai promotes the rapid development of the industry by vigorously developing the investment and financing system of the biomedical industry, such as the establishment of the equity investment fund of Shanghai Science and technology innovation center, focusing on the strategic emerging industries including biomedicine; the establishment of the equity investment fund of Shanghai biomedical industry, with the total target scale of 50 billion yuan, the first phase scale of 10 billion yuan, focusing on undertaking and gathering global students Advantageous resources of the pharmaceutical industry In recent years, Shanghai has issued a series of policy documents from early research and development, industrial promotion, clinical development, transformation, industrialization, market promotion, talent promotion and other aspects, from the top-level design to guide the development of Shanghai Medical and health industry, and promote the optimization and upgrading of regional industrial structure In the aspect of early R & D and industrial promotion, Shanghai has successively formulated such promotion policies as the 13th five year plan for the development of medical science and technology innovation in Shanghai, the implementation opinions of the general office of the municipal government on promoting the healthy development of the biomedical industry in Shanghai, and the implementation opinions on promoting the development of medical science and technology innovation in Shanghai, promoting the development of key varieties, key fields and innovation platforms Industrial development In terms of clinical development, Shanghai launched the 13th five year plan for the establishment of medical institutions in Shanghai, which effectively promoted the development of biomedical industry in Shanghai from the aspects of clinical trial platform, clinical trial liability insurance, key diseases, multi center R & D cooperation, etc In terms of undertaking transformation, Shanghai launched policies such as "Shanghai action plan for promoting the transfer and transformation of scientific and technological achievements (2017-2020)", which promoted the transformation of industry, University and research by focusing on the advanced fields of the industry, building the national scientific and technological achievements transformation center, and promoting technology transactions In terms of industrialization, following the national policy, Shanghai introduced the consistency evaluation of generic drugs and the system of drug listing license holders Meanwhile, as a pilot area of domestic medical device registration system, Shanghai also introduced the system of medical device listing license holders In terms of market promotion, Shanghai has successively issued a number of industrial promotion policies in recent years, including the notice on implementing the "two vote system" in the drug procurement of public medical institutions (for Trial Implementation), the pilot scheme for deepening the comprehensive reform of the medical and health system in Shanghai (2016-2020), striving to eliminate local protection and deepen the reform of the medical system In the formulation of talent promotion policies, Shanghai experienced 201
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.